Doxycycline-Regulated Vector for Inducible GDNF Expression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for delivering neurotrophic factors like GDNF in neurodegenerative diseases lack control over timing and magnitude of gene expression, leading to potential side effects and limited therapeutic efficacy due to chronic delivery.

Innovation Solution

Development of a doxycycline-regulated vector system for inducible and reversible expression of GDNF in human induced pluripotent stem cell-derived neural progenitor cells, allowing for controlled secretion of GDNF in response to tetracycline administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If constitutive growth factor release is used, then therapeutic effect is maintained, but side effects and desensitization occur

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent implements a dynamic gene expression system using doxycycline-regulated promoters that allow the growth factor secretion to be adjusted over time. The system transitions from static constitutive expression to dynamic controllable expression, enabling clinicians to modulate therapeutic delivery based on patient response and minimize side effects.

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent changes the expression parameter of the growth factor gene from constant (constitutive) to variable (inducible) through the use of doxycycline-regulated promoters. This allows precise control over the magnitude and timing of gene expression, enabling optimization of therapeutic effect while reducing harmful side effects.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If sustained growth factor secretion is used, then therapeutic efficacy is improved, but aberrant sprouting and desensitization occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidaberrant sprouting

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent enables periodic administration of doxycycline to control growth factor secretion in pulses rather than continuous sustained release. This periodic induction allows therapeutic efficacy to be achieved while providing intervals for receptor resensitization and preventing aberrant sprouting associated with continuous exposure.

Inventive Principle:

Principle #19Periodic action

3Duration of action of moving object

If growth factor delivery is continued long-term, then therapeutic benefit is maintained, but contraindications cannot be addressed

Engineering Contradiction:

Improvetherapeutic benefit durationVSAvoidflexibility to cease treatment

Core Design Contradiction:

Duration of action of moving objectVSAdaptability or versatility

Solution Approach 1:

The patent introduces doxycycline as an intermediary substance that mediates control over gene expression. This external mediator allows flexible cessation or resumption of growth factor delivery by simply adjusting doxycycline administration, providing adaptability to address contraindications while maintaining long-term therapeutic capability.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables precise modulation of GDNF expression, reducing side effects and allowing for flexible dosing, thereby enhancing therapeutic efficacy and safety in treating neurodegenerative diseases such as ALS.

Implementation Method 1

Methodology Applied

Scientific EffectTetracycline regulation of gene expression:

Data Source

PatentUS12258571B2Methods and compositions for inducible expression of neurotrophic factors

Publication Date: 2025.03.25 CEDARS SINAI MEDICAL CENT

AI summary

Delivery of glial cell line-derived neurotrophic factor (GDNF) has provided benefits to Parkinsonian patients and is currently being tested in a Phase 1/2a clinical trial for ALS patients. However, chronic trophic factor delivery prohibits dose adjustment or shut off in the event of side effects. To address this, the Inventors engineered a stably integrating, third-generation doxycycline-regulated vector, allowing inducible and reversible expression of a therapeutic molecule Human iPSC-derived neural progenitors were stably transfected with the vector, expanded and transplanted into the adult mouse brain. The Inventors observed that the addition and withdrawal of doxycycline led to GDNF expression that could be induced and reversed multiple times, demonstrating that doxycycline can penetrate the graft and regulate transgene expression in vivo. The Inventors' findings provide a proof of concept for combining gene and stem cell therapy for effective modulation of ectopic protein expression in transplanted cells.